GlassScriptPhysician profile
Jeffrey Kaufman
NPI 1437157088
$17,164.77
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $742 · 2021: $432.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,102.80 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $4,383.91 | 2019-2021 | |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.89 | 2019-2021 | |
| United Therapeutics Corporation | $122.71 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $85.70 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $79.16 | 2019-2020 | |
| Grifols USA, LLC | $68.72 | 2020-2021 | |
| Philips North America LLC | $61.24 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $60.68 | 2019-2021 | |
| Genzyme Corporation | $54.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.46 | 2019 | |
| Merck Sharp & Dohme LLC | $34.30 | 2019-2021 | |
| Genentech USA, INC. | $14.37 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $12.45 | 2019 | |
| Pfizer INC. | $12.01 | 2020 | |
| Circassia INC. | $11.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.